Preventing and controlling influenza virus infection remains a global public health
challenge, as it causes seasonal epidemics to unexpected pandemics. These infections are …

The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …

Background: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).
Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in …

These clinical practice guidelines are an update of the guidelines published by the
Infectious Diseases Society of America (IDSA) in 2009, prior to the 2009 H1N1 influenza …

Background Baloxavir marboxil is a selective inhibitor of influenza cap-dependent
endonuclease. It has shown therapeutic activity in preclinical models of influenza A and B …

Influenza affects approximately 1 billion individuals each year resulting in between 290,000
and 650,000 deaths. Young children and immunocompromised individuals are at a …

Flu is a serious health, medical, and economic problem, but no therapy is yet available that
has satisfactory results and reduces the occurrence of these problems. Nearly 20 years after …

Baloxavir acid (BXA), derived from the prodrug baloxavir marboxil (BXM), potently and
selectively inhibits the cap-dependent endonuclease within the polymerase PA subunit of …

Background Baloxavir marboxil (hereafter baloxavir), a selective inhibitor of influenza cap-
dependent endonuclease, was approved in 2018 in the USA and Japan for the treatment of …

Effective antivirals provide crucial benefits during the early phase of an influenza pandemic,
when vaccines are still being developed and manufactured. Currently, two classes of viral …